Trials / Unknown
UnknownNCT01604057
Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass
A Parallel Group Study to Evaluate the Effect of Six Weeks of Treatment With Nasal Spray (NS) ZT-034, Compared to Subcutaneous (SC) Forteo and Placebo, on Bone Formation, as Assessed by Stimulation of Serum P1NP Levels in Postmenopausal Women With Low Bone Mass
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Azelon Pharmaceuticals · Industry
- Sex
- Female
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to evaluate the effect treatment has on serum P1NP levels, a biomarker of bone formation in postmenopausal women with low bone mass.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZT-034 Low Dose Nasal Spray | Nasal Spray |
| DRUG | ZT-034 Mid Dose Nasal Spray | Nasal Spray |
| DRUG | ZT-034 High Dose Nasal Spray | Nasal Spray |
| DRUG | Teriparatide | 20 mcg subcutaneous daily |
| DRUG | Placebo | Nasal Spray |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2012-07-01
- Completion
- 2012-07-01
- First posted
- 2012-05-23
- Last updated
- 2012-05-23
Source: ClinicalTrials.gov record NCT01604057. Inclusion in this directory is not an endorsement.